Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2015

View Archived Issues

AC Immune collaborates with Janssen on anti-Tau vaccines for Alzheimer's

Mundipharma, Purdue and Esteve join forces to develop products for pain management

Amgen collaborates with MD Anderson to develop BiTE therapies for myelodysplastic syndrome

Celgene licenses ex-U.S. rights to Agios' AG-120

MedImmune licenses Omnis Pharmaceuticals oncolytic virus therapy

Precision Biologics discloses interim survival data for NPC-1C in metastatic colorectal cancer

Drug candidate induces host-protective immune cells in visceral leishmaniasis

Novel class of antibacterial compounds targeting Mur2 ligase described

Second Genome advances SGM-1019 in phase I trial

MaRS, J&J and Janssen to advance cardiac, diabetes and depression technologies

Mersana Therapeutics expands antibody-drug conjugate collaboration with Takeda

Sarepta gives updates on two DMD trials

OncoSec Medical to initiate pilot study in triple negative breast cancer

Companies forge immuno-oncology clinical trial collaborations

Promising results presented for chimeric antigen receptors in B-cell cancer treatment

Adimab expands collaboration with GSK, establishes new agreements

Tekmira Pharmaceuticals and OnCore Biopharma confirm merger agreement

Bayer researchers prepare new BUB1 inhibitors for cancer

Scientists at Lupin disclose novel CRAC modulators

New nicotinic acetylcholine receptor modulators designed by Lupin

Seragon patent reports new ER modulators for cancer

First biosimilar insulin agent approved in Japan

FDA grants orphan drug designation to SD-809 for Tourette's syndrome in children

Hospira submits BLA for epoetin alfa biosimilar Retacrit

FDA approves medical device to treat obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...